AstraZeneca Results Presentation Deck
H1 2021: total revenue +18%
Vaccine contributed 9% of growth
Total revenue growth, per cent
Total revenue excl. pandemic COVID-19 vaccine
up by 9% in H1 2021 and by 12% in Q2 2021
™
FY 2015
FY 2016
FY 2017
Q1 2018
Q2 2018
Q3 2018
14% 11% 18% 22% 5% 17% 11%
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
3%
Q3 2020
10%
Q4 2020
4%
7%
Q1 2021
13%
12%
Total revenue excluding pandemic COVID-19 vaccine (with negative growth in dark grey) Pandemic COVID-19 vaccine
Changes at CER.
7
Q2 2021
Brilinta
Bevespi
Koselugo
Lokelma
New medicines the
major contributor
+$1.7bn
incremental revenue of the new
medicines compared to H1 2020¹
Enhertu
Breztri
roxadustat
Fasenra
Lynparza
Imfinzi
Tagrisso
Calquence
Farxiga
Oncology New CVRM Respiratory & Immunology
Absolute values at CER. 1. Total revenue for Farxiga, Tagrisso, Calquence, Imfinzi, Lynparza, Fasenra, roxadustat, Breztri,
Enhertu, Lokelma, Koselugo, Bevespi and Brilinta.
$m
550
450
350
250
150
50
-50
-150
3View entire presentation